<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   ProStrakan Group plc
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       238305044
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       134881
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Kyowa Kirin International (KKI) focuses on developing and commercializing therapies in areas such as bone and skeletal conditions, women's health, and issues relating to the aging male. Its research is based in the areas of oncology, central nervous system, and nephrology. KKI's marketed products include pain medication Abstral, bone therapy Adcal, pain ointment Rectogesic, nausea treatment Sancuso, and testosterone gel Tostran. Its offerings are sold primarily in Europe and North America. The company was founded as Strakan in 1995, and was acquired by Japan's
   <company id="56869">
    Kyowa Hakko Kirin
   </company>
   (KHK) in 2011 before taking on the new owners' branding in 2016.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   Kyowa Kirin International (KKI) has research and development facilities at its headquarters in Scotland, and has commercial offices in London, across the EU, and in New Jersey.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Sales and Marketing.flsnp" />
  <p>
   KKI sells its products through sales team operating across the UK. It also has a network of worldwide distribution partners.
  </p>
  <p>
   As well as a direct sales force, Kyowa sells through its KHK affiliates and third parties.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Financial Performance.flsnp" />
  <p>
   In fiscal 2016, the parent company reported that international revenue fell due to the impact of yen appreciation and a decline in licensing revenue. Sales of Abstral and PecFent both increased, as did Cognizin in the US, which was adopted in a nationwide healthfood chain's supplement series.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   KKI acquired the rights to
   <company id="59531">
    AstraZeneca
   </company>
   's Moventig, a constipation treatment drug, in the EU plus Iceland, Norway, Switzerland, and Liechtenstein. KKI paid $70 million. The purchase opened up opportunities to serve both cancer and non-cancer chronic pain patients.
  </p>
  <p>
   The company is making progress in the development of biosimilar bevacizumab, as part of a joint venture with AstraZeneca.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Company Background.flsnp" />
  <p>
   ProStrakan was acquired by Kyowa Hakko Kirin for some $475 million in 2011. The firm delisted from the London Stock Exchange at that time. It was originally founded by former chairman Harry Stratford in 1995; the company's name was first changed from Strakan to ProStrakan when Strakan merged with ProSkelia in 2004, and then to Kyowa Kirin International in 2016 after the 2011 acquisition by Kyowa Hakko Kirin.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
